Clinical trials: Dalteparin
Deep-Vein Thrombosis
Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study
The purpose of this clinical research study is to assess efficacy and safety of 3 doses of apixaban 5 mg twice a day, 10 mg twice a day and 20 mg once daily versus conventional treatment with low molecular weight heparin or…
- Trial name
- NCT00252005
- Testing
- Apixaban
- Where
- 72 sites in United States, Australia and 9 more
- Volunteers
- 520 people
- Sponsor
- Bristol-Myers Squibb
Thrombosis
Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services
The purpose of this research is to gain insight into the way in which physicians adopt new practice techniques. In particular, we are interested in how medical innovations diffuse throughout social networks.
- Trial name
- NCT00203970
- Testing
- Observation
- Where
- United States
- Volunteers
- 645 people
- Sponsor
- University of Chicago
Fetal Growth Abnormality, Fetal Growth Restriction
Sildenafil Versus Low Molecular Weight Heparin in Fetal Growth Restriction Treatment
comparing the effect of using sildenafil citrate and LMWH in treatment of cases of IUGR due to placental insufficiency
- Trial name
- NCT03230162
- Testing
- Sildenafil, low molecular weight heparin
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Congenital Heart Disease, Unfractionated Heparin
Comparison of the Best Method for Measuring Anti-Xa Activity in Children Receiving Unfractionated Heparin in Cardiac Intensive Care (COMPAXE-HNF)
This study aims to compare the accuracy of two different blood sampling methods from a central venous catheter (CVC) for measuring anti-Xa activity in children receiving unfractionated heparin (UFH) from this CVC.
- Conditions
- Congenital Heart Disease, Unfractionated Heparin, Anti Xa Activity
- Trial name
- COMPAXE-HNF (NCT07365670)
- Testing
- blood sampling for measuring anti-Xa activity, measurement of anti-XA activity
- Volunteers
- 22 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Critical Illness
Intravenous Versus Subcutaneous Administration of Low Molecular Weight Heparin for Thromboprophylaxis in Critically Ill Patients
Objective: To compare the pharmacokinetic profiles of intravenous versus subcutaneous route of administration of LMWH for thromboprophylaxis in critically ill patients
- Trial name
- NCT04982055
- Testing
- Nadroparin (intravenous Infusion), Nadroparin (subcutaneous group)
- Volunteers
- 60 people
- Sponsor
- Clinique Saint Pierre Ottignies
End Stage Renal Failure on Dialysis
Low Molecular Weight Heparin for Hemodialysis Anticoagulation
Low-molecular weight heparins (LMWHs) as well as Unfractionated heparin (UFH) is used as anticoagulation during hemodialysis (HD) therapy.
- Trial name
- NCT01356615
- Testing
- low molecular weight heparin (enoxaparin sodium), standard unfractionated heparin
- Volunteers
- 27 people
- Sponsor
- Tehran University of Medical Sciences
Acute Kidney Injury, Deep Venous Thrombosis
Norwegian Intensive Care Unit Dalteparin Effect Study
The main purpose of the NORIDES study is to investigate the effect of pharmacological thromboprophylaxis with low molecular weight heparins (LMWHs) in critically ill patients, and how it is affected by presence of acute kidney…
- Trial name
- NORIDES (NCT01721928)
- Testing
- Continuous venovenous hemodialysis
- Where
- Norway
- Volunteers
- 70 people
- Sponsor
- Oslo University Hospital
Acute Coronary Syndrome, Venous Thromboembolism
The Effect of Reduced Dose of Enoxaparin on the Outcomes of Treatment With Enoxaparin
We hypothesize that reduced dose of enoxaparin in elderly patients will result in reduced proportion of patients with therapeutic anti Xa activity and reduced clinical efficacy.
- Conditions
- Acute Coronary Syndrome, Venous Thromboembolism, Atrial Fibrillation, Hypercoagulability
- Trial name
- NCT00354796
- Where
- Israel
- Volunteers
- 500 people
- Sponsor
- Hadassah Medical Organization
Percutaneous Coronary Intervention, Coronary Artery Disease (CAD)
Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)
The study investigates the safety and efficacy of PMX-60056 for the Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)
- Conditions
- Percutaneous Coronary Intervention, Coronary Artery Disease (CAD), Angioplasty
- Trial name
- NCT01312935
- Testing
- PMX-60056
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- PolyMedix, Inc.
Venous Thromboembolism, Pulmonary Thromboembolisms
Time of Treatment With LMWH in Cancer Patients With Thromboembolic Disease
Cancer is the most important acquired risk factor of thromboembolisms. More than 20% of all episodes of venous thromboembolism (VT) or pulmonary thromboembolisms (PT) are cancer related.
- Conditions
- Venous Thromboembolism, Pulmonary Thromboembolisms, Cancer
- Trial name
- NCT03134820
- Volunteers
- 352 people
- Sponsor
- Delos Clinical
Cerebral Vein Thrombosis, Deep Vein Thrombosis
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
This randomized phase III trial studies the side effects of and compares apixaban and dalteparin in reducing blood clots in patients with cancer-related venous thromboembolism.
- Conditions
- Cerebral Vein Thrombosis, Deep Vein Thrombosis, Gonadal Thrombosis, Hepatic Thrombosis
- Trial name
- NCT02585713
- Testing
- Apixaban, Dalteparin, Questionnaire Administration
- Where
- 18 sites in United States
- Volunteers
- 300 people
- Sponsor
- Academic and Community Cancer Research United
Coagulation Delay
Evaluation of Heparin Rebound in Cardiac Surgery
Recent work has shown that heparin rebound is common after cardiac surgery. The exact doze of protamine required to neutralize heparin at the end of CPB is unknown.
- Trial name
- NCT01675817
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Post Polypectomy Bleeding in Anticoagulated Patients, Gastrointestinal Hemorrhage
Hemorrhage Following Small Polyp Resection in the Colon in Anticoagulated Patients
One of the well-known of complications post colonic polypectomy is bleeding usually occuring in the 2-week period following the procedure. Patients treated with oral anticoagulation (e.g.
- Trial name
- NCT02375646
- Testing
- Warfarin, LMW Heparin
- Volunteers
- 286 people
- Sponsor
- Hadassah Medical Organization
Cancer, Deep Vein Thrombosis
Study on Thrombosis Therapy in German Cancer Patients
The study aims to document the flow of German patients with cancer and acute deep vein thrombosis from first visit to diagnosis and treatment, the applied diagnostic procedures, and therapy modalities.
- Conditions
- Cancer, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- NCT01559883
- Testing
- no intervention is being made
- Where
- Germany
- Volunteers
- 76 people
- Sponsor
- LEO Pharma
Ischemic Stroke
Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)
Ischemic stroke is caused by a blood clot that blocks the flow of blood to the brain and damages brain cells. The clot, or thrombus, is made up of platelets and fibrin.
- Trial name
- CATALIST (NCT00061373)
- Testing
- Aspirin, tinzaparin sodium, eptifibatide
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Pulmonary Thromboembolisms, Pulmonary Embolism
Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD
In selected patients with acute pulmonary embolism(PE), low dose (50mg/2h) recombinant tissue plasminogen activator (rt-PA) regimen had been reported to have less bleeding tendency than the FDA-approved rt-PA 100mg/2h regimen…
- Trial name
- NCT01531829
- Testing
- Recombinant tissue plasminogen activator (rt-PA), Low Molecular Weight Heparin
- Where
- 35 sites in China
- Volunteers
- 460 people
- Sponsor
- Beijing Chao Yang Hospital
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT)
Cancer Venous Thromboembolism (VTE)
The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of LMWH) compared with dalteparin for the prevention of the combined outcome of recurrent venous thromboembolism (VTE) or major…
- Conditions
- Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cancer
- Trial name
- NCT02073682
- Testing
- Edoxaban, Dalteparin, Low molecular weight heparin
- Where
- 9 sites in United States, Belgium and 4 more
- Volunteers
- 1,046 people
- Sponsor
- Daiichi Sankyo
Venous Thromboembolism, Pulmonary Embolism
A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients
Some cancer patients starting a new chemotherapy regimen are likely to develop blood clots, also known as venous thromboembolism (VTE). Blood clots can cause symptoms and can occasionally be life-threatening.
- Trial name
- PHACS (NCT00876915)
- Testing
- dalteparin injection
- Where
- 7 sites in United States, Canada
- Volunteers
- 218 people
- Sponsor
- University of Rochester
Stroke
LMWH-VTE Prophylaxis for Survivors of Acute Ischemic Stroke- Assessment of Standard Dosing Regimen
The anti-factor Xa (anti-Xa) assay is a functional assay that facilitates the measurement of antithrombin (AT)-catalyzed inhibition of factor Xa by unfractionated heparin (UFH) and direct inhibition of factor Xa by…
- Trial name
- NCT03593291
- Testing
- Anti Xa
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Loewenstein Hospital
Venous Thromboembolism
Thromboprophylaxis in Critically Ill Patients
Intensive care patients are at high risk to develop deep venous thrombosis and pulmonary embolism. Despite anticoagulation with heparin 7% of ICU patients suffer from this serious complication.
- Trial name
- NCT00437697
- Testing
- dalteparin
- Where
- Austria
- Volunteers
- 90 people
- Sponsor
- Medical University of Vienna